The disposal transaction of Zhuhai International Circuit is slated to be completed by end-October 2024, yet there are no updates on the said disposal. Disposal transaction having problems?

SESCO counterclaim of Rm342 million and the continuing closurerof the phosphate plant, resulting in 40 million losses , etc are potential risks.

As at June 30, 2024, Cape EMS’ balance sheet remained fundamentally strong with cash and cash equivalents of RM162.2 million, a low net gearing ratio of 0.03 times and net assets per share of 48 sen. Even if we write off the investment in Iconn, net assets per share will only decline to 41 sen. If CEB can maintain their product/market matrix for the coming quarters, their target price could easily exceed Phillips Securities target price. No funds or syndicates will tell you that they are buying. They are in the market to make money for themselves, not for the retailers.

Cape EMS paid US$16.5 million (approximately RM76.6 million) to take over iConn, a negative NTA company, hence recording a RM79.45 million goodwill. However the deal came with a profit guarantee of US$8 million for three years between 2024 and 2026 , or RM36 million - equivalent to Rm12 per year.
Why buy a negative NTA company with a factory in China for a hefty price of RM76.6 million? Do the Turkish American sellers provide any bank guarantee for the profit guarantee? The March and June quarters include any profits from Iconn?
If Iconn is so profitable, why do the Turkish Americans sell 100%? The list goes on.
So far , no sign of corporate or institutional buying - only syndicates , PDTs, stockists, day traders, retailers are buying.

Some financial media reported that CEB had cash of RM59.63 million on total borrowings of RM159.45 million. Its misleading as CEB also had cash equivalents ( money market instruments) and fixed deposits of RM106.6 million.
Also in its books are RM85.7 million in goodwill on acquisition, and trade receivables of RM220.94 million — up from RM177.58 million the year ago. The goodwill of RM85.7 million amounts to only 8.6 sen per share whilst its Net Assets is 47 sen. Also the increase in trade receivables is due to higher sales , only a 4.3 months debtors collection period.
There's nothing amiss in irs financial statements. Only the CEO over trade.

Price will drop further if the purchase of Iconn Incorporated runs into problems or CEB faces other operational problems. Just a revised profit guidelines of lower profits will not cause the stock to plunge.

If price is undervalued, why the major shareholders, directors n employees not buying now? Remember CEB paid Rm76 million for a 100% stake in Iconn Incorporated, a US based company?

CEB dropped more than 30% over 2 days n yet Bursa does not query. What happens to their purchase of a 100% stake in Iconn Incorporated, a US based company?

BSL- WB so cheap at 0.05 sen expiring in 2026 only. Foreign funds will buy . Buy 100 million warrants only cost them Rm500,000 or USD106,000. Expect Ringgit to rise further. Just a small push up, the foreign funds gonna make lots of money.

Why are some brokers asking for cash upfront to buy SCIB shares?

Net profit Myr 6.1 million. Dividend of
0.50 sen. Higher gloves production will be super good for Samchem.

Stripping the one off gain of Rm354 million, MBSB QTR 4 profit will slip into a loss of Rm52.9 million, pulled down by poor margin interest mix.

QR also reported contingent liability of Rm342 million to SESCO. Also reported segment loss of Rm57 on phosphate operations. It's very costly to leave the phosphate operations suspended n not to come to some settlement with SESCO.

BSl latest qtr results - small loss .Net assets still intact at 11 sen, with cash balance at at Rm134.5 millions or 6.0 sen per share. Short term n long term bank loans only Rm11.12 millions ,less than 0.6 sen per share.

A company with good product mix but lost its direction. Quarrel with their energy supplier n not able to get licences for it's phosphate mining products.

If it's true that Datuk Seri n Tan Sri were questioned by MACC, it shd fall further.

What will happen to their sales revenue if there is a crackdown on all these slot machines clubs?

Q2 profit not bad at Rm8 451 mill or 3.19 sen per share. Very strong balance sheet with cash and short term funds at Rm78 mil or 29 sen per share. Good growth for their manufacturing and hotel divisions.

No worries, CMSB phosphate complex will get their licences n start commercial production soon. Then price will uptrend n fly. The total investment for the first phase is about RM898m, funded via shareholder’s equity and long-term loans. The entire complex when completed will have an annual production capacity of 500,000 MT of food, feed, and fertiliser phosphate additives, 100,000 MT of ammonia, and 900,000 MT of coke.

CMSB shareholding:
Majaharta. 12.55%
Lejla Taib (deceased) 10.33
Lembaga Tabung Haji. 7.34
Swak Econ Dev Corp. 5.67
EPF 3.79
--------
39.63%
Sulaiman legal actions against his step mother were related to the transfer of shares of a private company. Nothing to do with CMSB.

Edelteq Holdings Bhd made its debut on the ACE Market of Bursa Malaysia at 75 sen, a 212.5% premium over its issue price of 24 sen. Edelteq is just a engineering support provider for integrated circuit assembly and test process in the semiconductor industry. Silterra of Dnex is a full fledged semiconductor wafer foundry with greater sales potential. Mr Market will notice the price difference n will certainly rally Dnex share price.

The tax expenses of Rm277.9 mill includes the deferred tax expense of Rm252 mill, engendered by the Energy Profit Levy (“EPL”), a temporary levy
introduced by UK Government on 14 July 2022. The EPL was set at 25% for profits arising from 26 May 2022 to
31 December 2022 and 35% for profits arising from 1 January 2023 to 31 March 2028. The deferred tax expense is provision for future tax obligation which is
expected to
be reversed ( credit back as gain) during the window for which the EPL regime applies, i.e. up to 31 March 2028 .
Taking out the deferred tax of Rm252.4 mill from the attributable loss of Rm239.8, you will get attributable profit of Rm12.6. Think selling is grossly overdone.

CMSB Annual Report 2022 has been completed n will be presented to the shareholders at the coming AGM on 26/05/23.
CMPI (formerly known as Malaysia Phosphate Additives Sarawak Sdn Bhd) had already referred a dispute involving the PPA to the Asian International Arbitration Centre under the dispute resolution mechanism of the PPA. The disputed amount of Rm266 million has been disclosed as contingent liability in the Annual Report 2022.
CMSB , MPA (Malaysia Phosphate Additives) n Tradewinds Plantation set up CMPI with shareholding of 60%, 27% n 13% respectively. Khazanah has 40% shareholding in MPA.
Don't think SESCO would want to sink CMPI operations, causing financial n commercial harm to Sarawak industrial eco system.

No, it's not margin call as the price has been stable before Thursday sell down. Margin call only if price drops below the maintenance margin requirement. Smart money leaving, possibly due to high customers concentration, expensive as compared to peers - Master PE only 6, PPHB PE only 4.9 whilst DSS PE is 15.9.

Their top 5 clients constitute 70% of their revenue. If one big client cancel order, it will greatly impact their net profit. Dec qtr EPS dropped to only 0.75 Sen from 3.38 Sen in Sept qtr.

Heard CMSB dropped heavily due to news of subscription for a capital call of RM 315,649,514.00, for a total of 315,649,514 shares in Cahya Mata Phosphates (at Rm1.00 per share) . Some thought that the capital call was meant for CMSB, hence they sell. Stay invested - CMSB has net cash backing per share of 39.80 sen n RHB-OSK set its TP at Rm1.60.

Vizione Nov qtr results out soon. New projects in the pipeline.

MI reported a net profit of RM18.7m (+46% QoQ) in 2QFY22 (driven by customers’ capex expansions and the strengthening USD against both MYR and NTD , not sales of land), bringing its bottomline to RM31.5m (+6.4% YoY) in 1HFY22. Cash per share is 42 Sen, with minimal debts.

Latest Q2 report - high short term borrowing at Rm257.9 million n low cash flow. Why current borrowing so high?

Q1 2022 net profit Rm3.038 millions or 1.17 sen per share. Expect even better results for Q2 plus possible dividend of 1 sen, giving dividend yield of 4.35%

CMSB cost - only Rm157 mil. n selling for Rm527 mil , or 49 Sen per share. Expect special dividend.

Olympia - possible unlocking value in its property n financial assets.

Before rights issue, Vizione NTA is 56 sen, Cash at Bank n FD 42 million, long term bank borrowing 8 million , short term bank borrowing 37 million. With rights issues proceeds , Vizione will be able to clinch more jobs, now book orders more than Rm 3 billion.

Buy the warrant WE for duit Raya

The first SPA is for the acquisition of Oilfield and its nine subsidiaries as well as a 48% equity interest in Scomi KMC Sdn Bhd (“Scomi KMC”) from Scomi Energy for a cash consideration of RM13.5 million. The second SPA involves Oiltools International acquiring from Scomi Oiltools Sdn Bhd (Receiver & Manager appointed) (“SOSB”) a 4% equity interest in Scomi KMC, 25% equity interest in Scomi Oiltools Gulf W.L.L. and 25% equity interest in Continental Wire Cloth (Malaysia) Sdn Bhd (formerly known as Global Oilfield Products Sdn Bhd) for a cash consideration of RM2.6 million. Through the first and second SPAs, Oiltools will hold 52% equity interest in Scomi KMC.

The third SPA is for the acquisition of a 5-storey shop office located in Dataran Prima, Petaling Jaya, Selangor by Oilfield International from SOSB while the fourth SPA is for Oilfield International’s acquisition of the inventory and equipment from SOSB for a total cash consideration of RM3.0 million and RM1.9 million respectively.

For the period under review, Scomi Oilfield Ltd revenue was higher than the corresponding period
in the preceding year by approximately RM1.6 million. The marginal increase was
mainly attributed to the improving performance in India and Pakistan.
The Group reported a pre-tax loss of RM3.4 million for the period under review against
the pre-tax loss of RM29.4 million for the corresponding period. The higher pre-tax
loss in the preceding year was mainly a result of unrealised foreign exchange loss for
the period amounting to RM17.7 million.

Yesterday lots of RSS n PDTs short selling. Those who short by borrowing scrips will hv to buy back.

NTA - Rm2.80. Cash at Bank Rm545 millions or 51 sen . per share. Investment in associate company n joint venture - about Rm1.3 billions or 1.21 per share. Short term security investment - Rm407 millions or 21 sen per share. Not only quite safe, it's very undervalued due to its upcoming projects, govt approval for its cement price increase, better dividend payout ,etc ,etc

Texchem Q4 results going to be very good. Someone here mentioned Rm15 to 20 mil. Buy Texchem for its turnaround story n not it's acquisition story.

Expect strong Q4 - 7 to 12 mil

Think the additional LTIP at 15% of share capital to be priced at not more than 65.5 sen. It's Long Term Incentive Plan for directors , don't think they want to price too high .

Wong has proposed private placement since Sept 2021, so far no action. Now propose additional LTIP at 15% of share capital. Believe they won't price the PP n LTIP at above 60 sen

475,295,394 NEW ORDINARY SHARES IN SAUDEE GROUP BERHAD at 15 sen, 2 rights with 1 free warrant for 1 share, completed in May 2021. Total rights proceeds amounted to Rm71.294 millions, less corporate fees of Rm883k, balance = Rm70.411 millions or 9.8sen per share of enlarged capital of 716 million issued capital. The balance of Rm70.411 millions is for the repayment of loan, construction of cold rooms, expansion of production capacity, investment in similar business, etc. With the MCO n EMCO in force, Saudee will not be able to carry out their investment and spending plans. It's mind boggling that with a rights issue cash of at least 9.8 sen per enlarged share capital, some parties are actively pushing the shares down as if the company is going bankrupt. Bursa should investigate.

UBS , CS r collecting at 1.810 n 1.82. Surprise that EPF is not buying as return is about 10.5% for period of less than 6 months.

Post removed.Why?

Some shareholders have been complaining to the Board to lift Insas out of its value trap. If Board agrees to just give 5% of its holding in Inari as dividend in specie, based on the median price of Rm3.40 for Inari, the dividend in specie will gives about 15 sen per share to the 693K plus Insas shareholders. Then the value trap conundrum will be lifted. Fully agree with post on Insas intrinsic value n earnings forecast -

"Its Nta is rm 2.83 per share loh!

Its intrinsic value when inclusive of inari mark to market gain exceed rm 5.00 per share mah...!!

Insas has a net cash exceeding Rm 0.90 per share woh!

When comes to earnings based on half year result insas profits is already rm 148m or eps 22.2 sen loh! "

Inari will be paying at least 4.5 Sen dividend for 2021. Insas holding of 544.8 mil Inari shares wld mean Rm24.5 mil dividend income or 3.5 sen per share based on Insas share capital of 693 miil shares. It's stock broking n other business will also be paying good dividend this year. Funds will be collecting.

BNM has rejected Generali takeover of 70% stake last year as BNM does not favour foreigners taking majority stake in fin inst. Look like MPHB has to find local buyer to sell its stake.

Unless BNM agrees to let Generali take majority stake over the insurance business, MPHB is still deemed a fin co , must comply with the margin of solvency requirement, hence cannot pay out dividend.

Solution price hovered around 0.20 before vaccines news . NTA only 0.1244. News to supply 3.5 millions Cansino vaccines. Assuming margin of Rm10 per bottle. 3.5 millions bottles only Rm35 million or Rm0.09 per share. After 2021, may not need so many vaccinations. ESOS
conversion to share is only Rm0.20. Need to be cautious.

Sale by Ng is not tru open market , but off market direct deal.. Expect new shareholder to come in.